Paul Bessette

Financement

• Subvention. DOVE: Detecting ovarian cancer earlier through the development of a diagnostic probability function. Canadian Institutes of Health Research (Ottawa, Canada). 220 687 $. (2007-2009).
  Numéro de subvention : 200703MOP. Voir plus

Publications

Articles

• Kim, S.I., Kim, J.-W., Kwon, J.S., Ferguson, S.E., Sebastianelli, A., Bessette, P., Mahner, S., Gauthier, T., de Kroon, C., van Driel, W., Williamson, K., Goffin, F., Polterauer, S., Eyjólfsdóttir, B., Lee, J.-Y., Maguire, P.J., Juhasz-Böss, I., Lim, H., Seol, A., ... Plante, M. (2026). Comparative outcomes of simple versus radical hysterectomy in patients with and without very low-risk early-stage cervical cancer: An exploratory analysis from the Gynecologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/ SHAPE trial. Gynecologic Oncology. DOI
• Mahner S, Trillsch F, Kwon JS, Ferguson SE, Bessette P, Sebastianelli A, Golfier F, Gauthier T, De Kroon C, van Driel W, Tidy J, Williamson K, Plante M. (2025). Surgical approach, preoperative LEEP/conization and patterns of recurrence and death in low-risk cervical cancer - exploratory analysis from the CCTG CX.5/SHAPE trial. International journal of surgery (London, England). DOI
• (2025). ATHENA-MONO Post-Progression Survival Data Update In Patients With Newly Diagnosed Advanced Ovarian Cancer. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• Post, C.C.B., de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Leary, A., Ottevanger, P.B., McCormack, M., Khaw, P., D'Amico, R., Fyles, A., Chargari, C., Kitchener, H.C., Do, V., Lissoni, A., Procencher, D., Genestrie, C., Nijman, H.W., ... Creutzberg, C.L. (2025). Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial. Obstetrical Gynecological Survey. DOI
• Post, C.C.B., de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Leary, A., Ottevanger, P.B., McCormack, M., Khaw, P., D'Amico, R., Fyles, A., Chargari, C., Kitchener, H.C., Do, V., Lissoni, A., Provencher, D., Genestie, C., Nijman, H.W., ... Creutzberg, C.L. (2025). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. Lancet Oncology. DOI
• Marth, C., Moore, R.G., Bidziński, M., Pignata, S., Ayhan, A., Rubio, M.J., Beiner, M., Hall, M., Vulsteke, C., Braicu, E.I., Sonoda, K., Wu, X., Frentzas, S., Mattar, A., Lheureux, S., Chen, X., Hasegawa, K., Magallanes-Maciel, M., Choi, C.H., ... Bollinger, L. (2025). First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. DOI
• Plante, M., Mahner, S., Sebastianelli, A., Bessette, P., Lambaudie, E., Guyon, F., Piek, J., Smolders, R., Tidy, J., Williamson, K., Hanker, L., Goffin, F., Tsibulak, I., Eyjolfsdottir, B., Gleeson, N., Lee, J.-Y., Ke, Y., Kwon, J.S., Ferguson, S.E., ... Tu, D. (2025). Minimally invasive compared to open surgery in patients with low-risk cervical cancer following simple hysterectomy: An exploratory analysis from the Gynegologic Cancer Intergroup/Canadian Cancer Trials Group CX.5/SHAPE trial. International Journal of Gynecological Cancer. DOI
• Plante M, Kwon JS, Ferguson S, Samouëlian V, Ferron G, Maulard A, de Kroon C, Van Driel W, Tidy J, Williamson K, Mahner S, Kommoss S, Goffin F, CX.5 SHAPE Investigators. (2024). Simple versus Radical Hysterectomy in Women with Low-Risk Cervical Cancer. The New England journal of medicine. DOI
• (2024). Minimally invasive versus open surgery in patients with low risk cervical cancer who underwent simple hysterectomy; an exploratory analysis from the CCTG cx.5/shape trial cx.5/shape trial. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• Kaya, M., Post, C.C.B., Tops, C.M., Nielsen, M., Crosbie, E.J., Leary, A., Mileshkin, L.R., Han, K., Bessette, P., de Boer, S.M., Jürgenliemk-Schulz, I.M., Lutgens, L., Jobsen, J.J., Haverkort, M.A.D., Nout, R.A., Kroep, J., Creutzberg, C.L., Smit, V.T.H.B.M., Horeweg, N., ... Bosse, T. (2024). Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation. Modern Pathology. DOI
• (2024). Surgical approach, preoperative LEEP/cone biopsy and patterns of recurrence and death in low-risk cervical cancer - analysis of the international CCTG CX.5/SHAPE phase III trial. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• (2024). Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer. RADIOTHERAPY AND ONCOLOGY.
• Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. (2023). Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer. The New England journal of medicine. DOI
• El-Zein M, Ali R, Farah E, Botting-Provost S, Franco EL, Survey Study Group. (2023). Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management: cross-sectional survey of healthcare professionals. eLife. DOI
• Cyr, M.-P., Dostie, R., Camden, C., Dumoulin, C., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Mayrand, M.-H., Morin, M. (2023). Acceptability of multimodal pelvic floor physical therapy to treat dyspareunia after gynecological malignancies: a qualitative study of women’s views and experiences. International Urogynecology Journal. DOI
• Cyr, M.-P., Camden, C., Dumoulin, C., Dostie, R., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Mayrand, M.-H., Morin, M. (2023). Gynecological Cancer Survivors’ Experiences of Dyspareunia and Factors Influencing Care-Seeking Behavior: A Qualitative Study. Archives of Sexual Behavior. DOI
• Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Study 309–KEYNOTE-775 Investigators. (2022). Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. The New England journal of medicine. DOI
• Paquette, M., Espinosa-Bentancourt, E., Lavallée, E., Phoenix, S., Lapointe-Milot, K., Bessette, P., Guérin, B., Turcotte, E.E. (2022). 18F-4FMFES and 18F-FDG PET/CT in Estrogen Receptor-Positive Endometrial Carcinomas: Preliminary Report. Journal of Nuclear Medicine. DOI
• Monk, B.J., Parkinson, C., Lim, M.C., O'malley, D.M., Oaknin, A., Wilson, M.K., Coleman, R.L., Lorusso, D., Bessette, P., Ghamande, S., Christopoulou, A., Provencher, D., Prendergast, E., Demirkiran, F., Mikheeva, O., Yeku, O., Chudecka-Glaz, A., Schenker, M., Littell, R.D., ... Kristeleit, R.S. (2022). A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology. DOI
• Cyr, M.-P., Dumoulin, C., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Mayrand, M.-H., Morin, M. (2022). Changes in pelvic floor morphometry and muscle function after multimodal physiotherapy for gynaecological cancer survivors suffering from dyspareunia: a prospective interventional study. Physiotherapy United Kingdom. DOI
• (2022). EFFICACY ANALYSIS BY DISEASE RISK SUBGROUP FOR THE PHASE 3 ATHENA-MONO STUDY (GOG3020/ENGOT-OV45) EVALUATING RUCAPARIB MAINTENANCE TREATMENT IN PATIENTS WITH NEWLY DIAGNOSED OVARIAN CANCER. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• Cyr, M.-P., Dostie, R., Camden, C., Dumoulin, C., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Mayrand, M.-H., Morin, M. (2022). Improvements following multimodal pelvic floor physical therapy in gynecological cancer survivors suffering from pain during sexual intercourse: Results from a one-year followup mixed-method study. Plos One. DOI
• Wortman, B.G., Post, C.C.B., Powell, M.E., Khaw, P., Fyles, A., D'Amico, R., Haie-Meder, C., Jürgenliemk-Schulz, I.M., McCormack, M., Do, V., Katsaros, D., Bessette, P., Baron, M.H., Nout, R.A., Whitmarsh, K., Mileshkin, L., Lutgens, L.C.H.W., Kitchener, H.C., Brooks, S., ... de Boer, S.M. (2022). Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics. DOI
• Khaw, P., Do, V., Lim, K., Cunninghame, J., Dixon, J., Vassie, J., Bailey, M., Johnson, C., Kahl, K., Gordon, C., Cook, O., Foo, K., Fyles, A., Powell, M., Haie-Meder, C., D'Amico, R., Bessette, P., Mileshkin, L., Creutzberg, C.L., Moore, A. (2022). Radiotherapy Quality Assurance in the PORTEC-3 (TROG 08.04) Trial. Clinical Oncology. DOI
• (2022). Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase 3 ATHENA-MONO study. ANNALS OF ONCOLOGY. DOI
• (2022). Rucaparib maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC): Defining benefit according to disease risk subgroups within the phase III ATHENAeMONO study. ANNALS OF ONCOLOGY. DOI
• (2022). WOMEN'S EXPERIENCES OF DYSPAREUNIA AFTER GYNECOLOGICAL CANCER TREATMENT AND CARE-SEEKING BEHAVIOR: AN INSIGHT FROM A QUALITATIVE STUDY. JOURNAL OF SEXUAL MEDICINE.
• Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Gümüş M, KEYNOTE-826 Investigators. (2021). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. The New England journal of medicine. DOI
• Cyr, M.-P., Dumoulin, C., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Mayrand, M.-H., Morin, M. (2021). A Prospective Single-Arm Study Evaluating the Effects of a Multimodal Physical Therapy Intervention on Psychosexual Outcomes in Women With Dyspareunia After Gynecologic Cancer. Journal of Sexual Medicine. DOI
• Cyr, M.-P., Dumoulin, C., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Morin, M. (2021). Characterizing Pelvic Floor Muscle Function and Morphometry in Survivors of Gynecological Cancer Who Have Dyspareunia: A Comparative Cross-Sectional Study. Physical Therapy. DOI
• (2021). High diagnostic value of 18F-FDG PET/CT in detecting endometrial cancer in patients with precancerous endometrial lesions. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY. DOI
• Post, C.C.B., de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, N.P.B., Ledermann, J.A., Khaw, P., D'Amico, R., Fyles, A., Baron, M.H., Kitchener, H.C., Nijman, H.W., Lutgens, L.C.H.W., Brooks, S., Jürgenliemk-Schulz, I.M., Feeney, A., ... Creutzberg, C.L. (2021). Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial. International Journal of Radiation Oncology Biology Physics. DOI
• (2021). MOLECULAR PROFILING OF NSMP HIGH-RISK ENDOMETRIAL CANCERS OF THE PORTEC-3 TRIAL - PROGNOSTIC REFINEMENT AND DRUGGABLE TARGETS. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• Post, C.C.B., Stelloo, E., Smit, V.T.H.B.M., Ruano, D., Tops, C.M., Vermij, L., Rutten, T.A., Jürgenliemk-Schulz, I.M., Lutgens, L.C.H.W., Jobsen, J.J., Nout, R.A., Crosbie, E.J., Powell, M.E., Mileshkin, L., Leary, A., Bessette, P., Putter, H., De Boer, S.M., Horeweg, N., ... Creutzberg, C.L. (2021). Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. Journal of the National Cancer Institute. DOI
• (2021). Toxicity and patient-reported symptoms after 3D-conformal or intensity-modulated pelvic radiotherapy. RADIOTHERAPY AND ONCOLOGY.
• (2021). UNDERSTANDING THE EFFECTS OF MULTIMODAL PELVIC FLOOR PHYSIOTHERAPY IN GYNECOLOGICAL CANCER SURVIVORS WITH DYSPAREUNIA: A MIXED-METHOD RESEARCH STUDY WITH A 12-MONTH FOLLOW-UP. NEUROUROLOGY AND URODYNAMICS.
• (2020). 4FMFES and FDG-PET imaging in uterine cancer patients: preliminary assessment. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.
• (2020). EFFECTS OF PHYSIOTHERAPY TREATMENT ON THE PELVIC FLOOR MUSCLE FUNCTION AND MORPHOLOGY IN GYNECOLOGICAL CANCER SURVIVORS WITH DYSPAREUNIA: A PROSPECTIVE STUDY. NEUROUROLOGY AND URODYNAMICS.
• (2020). FEASIBILITY, ACCEPTABILITY AND EFFECTS OF PHYSICAL THERAPY TREATMENT FOR GYNECOLOGICAL CANCER SURVIVORS WITH DYSPAREUNIA. JOURNAL OF SEXUAL MEDICINE.
• Cyr, M.-P., Dumoulin, C., Bessette, P., Pina, A., Gotlieb, W.H., Lapointe-Milot, K., Mayrand, M.-H., Morin, M. (2020). Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventional study. Gynecologic Oncology. DOI
• (2020). Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. INTERNATIONAL JOURNAL OF CANCER. DOI
• (2020). Long-Term Quality of Life after (chemo)radiotherapy for high-risk Endometrial Cancer in PORTEC-3. RADIOTHERAPY AND ONCOLOGY.
• Mirza, M.R., Benigno, B., Dørum, A., Mahner, S., Bessette, P., Barceló, I.B., Berton-Rigaud, D., Ledermann, J.A., Rimel, B.J., Herrstedt, J., Lau, S., du Bois, A., Herráez, A.C., Kalbacher, E., Buscema, J., Lorusso, D., Vergote, I., Levy, T., Wang, P., ... Matulonis, U.A. (2020). Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecologic Oncology. DOI
• Leon-Castillo, A., De Boer, S.M., Powell, M.E., Mileshkin, L.R., Mackay, H.J., Leary, A., Nijman, H.W., Singh, N., Pollock, P.M., Bessette, P., Fyles, A., Haie-Meder, C., Smit, V.T.H.B.M., Edmondson, R.J., Putter, H., Kitchener, H.C., Crosbie, E.J., De Bruyn, M., Nout, R.A., ... Bosse, T. (2020). Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. Journal of Clinical Oncology. DOI
• (2020). PREVALENCE AND PROGNOSIS OF LYNCH SYNDROME AND SPORADIC MISMATCH REPAIR DEFICIENCY IN THE COMBINED PORTEC-1,-2 AND-3 ENDOMETRIAL CANCER TRIALS. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• Matte I, Garde-Granger P, Bessette P, Piché A. (2019). Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high grade serous ovarian cancer. American journal of cancer research.
• de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann, J.A., Khaw, P., D'Amico, R., Fyles, A., Baron, M.-H., Jürgenliemk-Schulz, I.M., Kitchener, H.C., Nijman, H.W., Wilson, G., Brooks, S., Gribaudo, S., Provencher, D., ... Tubiana-Mathieu, N. (2019). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncology. DOI
• Matte, I., Garde-Granger, P., Bessette, P., Piché, A. (2019). Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway. BMC Cancer. DOI
• (2019). LONG-TERM SAFETY ASSESSMENT OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER: RESULTS FROM THE ENGOT-OV16/NOVA TRIAL. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• (2019). LONG-TERM SAFETY OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER: RESULTS FROM THE ENGOT-OV16/NOVA TRIAL. ONCOLOGY NURSING FORUM.
• (2019). PROGNOSTIC RELEVANCE OF THE MOLECULAR CLASSIFICATION IN HIGH-RISK ENDOMETRIAL CANCER: ANALYSIS OF THE PORTEC-3 TRIAL. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. DOI
• (2019). Patterns of Recurrence and Survival in the Randomized Portec-3 Trial of Chemoradiotherapy for High-Risk Endometrial Cancer. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. DOI
• de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann, J.A., Khaw, P., Colombo, A., Fyles, A., Baron, M.-H., Jürgenliemk-Schulz, I.M., Kitchener, H.C., Nijman, H.W., Wilson, G., Brooks, S., Carinelli, S., Provencher, D., ... Tubiana-Mathieu, N. (2018). Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncology. DOI
• Lane, D., Matte, I., Garde-Granger, P., Bessette, P., Piché, A. (2018). Ascites IL-10 Promotes Ovarian Cancer Cell Migration. Cancer Microenvironment. DOI
• (2018). LONG-TERM SAFETY OF NIRAPARIB IN PATIENTS WITH RECURRENT OVARIAN CANCER (ROC): RESULTS FROM THE ENGOT-OV16/NOVA TRIAL. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER.
• Vergote, I., Coens, C., Nankivell, M., Kristensen, G.B., Parmar, M.K.B., Ehlen, T., Jayson, G.C., Johnson, N., Swart, A.M., Verheijen, R., McCluggage, W.G., Perren, T., Panici, P.B., Kenter, G., Casado, A., Mendiola, C., Stuart, G., Reed, N.S., Kehoe, S., ... Petru, E. (2018). Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncology. DOI
• Provencher, D.M., Gallagher, C.J., Parulekar, W.R., Ledermann, J.A., Armstrong, D.K., Brundage, M., Gourley, C., Romero, I., Gonzalez-Martin, A., Feeney, M., Bessette, P., Hall, M., Weberpals, J.I., Hall, G., Lau, S.K., Gauthier, P., Fung-Kee-Fung, M., Eisenhauer, E.A., Winch, C., ... MacKay, H.J. (2018). OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Annals of Oncology. DOI
• Provencher, D.M., Gallagher, C.J., Parulekar, W.R., Ledermann, J.A., Armstrong, D.K., Brundage, M., Gourley, C., Romero, I., Gonzalez-Martin, A., Feeney, M., Bessette, P., Hall, M., Weberpals, J.I., Hall, G., Lau, S.K., Gauthier, P., Fung-Kee-Fung, M., Eisenhauer, E.A., Winch, C., ... Mackay, H.J. (2018). OV21/PETROC: A randomized gynecologic cancer intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Obstetrical and Gynecological Survey. DOI
• (2018). Patterns of recurrence in the randomised PORTEC-3 trial of chemoradiotherapy for endometrial cancer. RADIOTHERAPY AND ONCOLOGY. DOI
• (2018). Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent. STRUCTURE. DOI
• (2017). Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer. JOURNAL OF CLINICAL ONCOLOGY. DOI
• Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, ENGOT-OV16/NOVA Investigators. (2016). Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. The New England journal of medicine. DOI
• Lane, D., Matte, I., Laplante, C., Garde-Granger, P., Carignan, A., Bessette, P., Rancourt, C., Piché, A. (2016). CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Molecular Cancer. DOI
• Matte, I., Legault, C.M., Garde-Granger, P., Laplante, C., Bessette, P., Rancourt, C., Piché, A. (2016). Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clinical and Experimental Metastasis. DOI
• (2016). OV21/PETROC: A randomized Gynecologic Cancer Intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). JOURNAL OF CLINICAL ONCOLOGY. DOI
• de Boer, S.M., Powell, M.E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P.B., Ledermann, J.A., Khaw, P., Colombo, A., Fyles, A., Baron, M.-H., Kitchener, H.C., Nijman, H.W., Kruitwagen, R.F., Nout, R.A., Verhoeven-Adema, K.W., Smit, V.T., Putter, H., Creutzberg, C.L. (2016). Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology. DOI
• du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, AGO Study Group led Gynecologic Cancer Intergroup/European Network of Gynaecologic Oncology Trials Groups Intergroup Consortium. (2015). Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Oncology. DOI
• Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, ICON7 trial investigators. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet. Oncology. DOI
• (2015). A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650). GYNECOLOGIC ONCOLOGY. DOI
• (2015). Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial. JOURNAL OF CLINICAL ONCOLOGY. DOI
• Mahner, S., Meier, W., Du Bois, A., Brown, C., Lorusso, D., Dell'Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A.G., Vergote, I., Vasey, P., Pujade-Lauraine, E., Gladieff, L., Ferrero, A. (2015). Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. European Journal of Cancer. DOI
• (2015). RELATION BETWEEN PATIENT AND PHYSICIAN REPORTED TOXICITY IN THE RANDOMISED PORTEC-3 TRIAL OF RADIATION THERAPY (RT) WITH OR WITHOUT CHEMOTHERAPY FOR ENDOMETRIAL CANCER. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER.
• Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, EORTC GCG and EORTC GCG Translational Research Group. (2014). Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. DOI
• Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I, European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group. (2013). Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy. Gynecologic oncology. DOI
• (2013). Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index. SCIENCE TRANSLATIONAL MEDICINE. DOI
• Litim N, Labrie Y, Desjardins S, Ouellette G, Plourde K, Belleau P, INHERIT BRCAs, Durocher F. (2012). Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population. Molecular oncology. DOI
• Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV, Takefman J, Grigorie MS, Artho G, DOvE Study Group. (2012). Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. The Lancet. Oncology. DOI
• Brassard, L., Bessette, P. (2012). Value of gynecological cytology and CA 125 level for predicting extrauterine malignancy in endometrial cancer,Valeur de la cytologie gynécologique et du taux de CA 125 pour la prévision de la maladie extra-utérine dans les cas de cancer de l'endomètre. Journal of Obstetrics and Gynaecology Canada. DOI
• Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, ICON7 Investigators. (2011). A phase 3 trial of bevacizumab in ovarian cancer. The New England journal of medicine. DOI
• Dorval M, Noguès C, Berthet P, Chiquette J, Gauthier-Villars M, Lasset C, Picard C, Plante M, INHERIT BRCAs, GENEPSO Cohort, Simard J, Julian-Reynier C. (2011). Breast and ovarian cancer screening of non-carriers from BRCA1/2 mutation-positive families: 2-year follow-up of cohorts from France and Quebec. European journal of human genetics : EJHG. DOI
• (2011). Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial. JOURNAL OF CLINICAL ONCOLOGY. DOI
• Keita, M., AinMelk, Y., Pelmus, M., Bessette, P., Aris, A. (2011). Endometrioid ovarian cancer and endometriotic cells exhibit the same alteration in the expression of interleukin-1 receptor II: To a link between endometriosis and endometrioid ovarian cancer. Journal of Obstetrics and Gynaecology Research. DOI
• Smith, G.N., McNamara, H., Bessette, P., Allen, V.M., Ross, S., Schulz, J., Pierson, R., Nadeau, B. (2011). Resident Research Training Objectives and Requirements of the Association of Academic Professionals in Obstetrics and Gynaecology. Journal of Obstetrics and Gynaecology Canada. DOI
• Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, NCIC Clinical Trials Group. (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England journal of medicine. DOI
• Guénard F, Pedneault CS, Ouellette G, Labrie Y, Simard J, INHERIT, Durocher F. (2010). Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer. Genetic testing and molecular biomarkers. DOI
• Keita, M., Bessette, P., Pelmus, M., Ainmelk, Y., Aris, A. (2010). Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes. Journal of Ovarian Research. DOI
• Plourde M, Ferland A, Soucy P, Hamdi Y, Tranchant M, Durocher F, Sinilnikova O, Luu The V, INHERIT BRCAs, Simard J. (2009). Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer. The Journal of steroid biochemistry and molecular biology. DOI
• Guénard, F., Labrie, Y., Ouellette, G., Joly Beauparlant, C., Durocher, F., Bessette, P., Bridge, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Simard, J. (2009). Genetic sequence variations of BRCA1-interacting genes AURKA, BAP1, BARD1 and DHX9 in French Canadian Families with high risk of breast cancer. Journal of Human Genetics. DOI
• Chênevert, J., Bessette, P., Plante, M., Têtu, B., Dubé, V. (2009). Mixed ovarian large cell neuroendocrine carcinoma, mucinous adenocarcinoma, and teratoma: A report of two cases and review of the literature. Pathology Research and Practice. DOI
• Desjardins, S., Beauparlant, J.C., Labrie, Y., Ouellette, G., Durocher, F., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Simard, J. (2009). Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer. BMC Cancer. DOI
• ASTEC/EN.5 Study Group, Blake P, Swart AM, Orton J, Kitchener H, Whelan T, Lukka H, Eisenhauer E, Bacon M, Tu D, Parmar MK, Amos C, Murray C, Qian W. (2008). Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet (London, England). DOI
• Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S, Tateo S, Franchi M, Jobsen JJ, Coens C, Teodorovic I, Vergote I, Vermorken JB, European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. (2008). Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). European journal of cancer (Oxford, England : 1990). DOI
• Waddell, G., Desindes, S., Takser, L., Beauchemin, M.-C., Bessette, P. (2008). Cervical Ripening Using Vaginal Misoprostol before Hysteroscopy: A Double-blind Randomized Trial. Journal of Minimally Invasive Gynecology. DOI
• Desjardins, S., Belleau, P., Labrie, Y., Ouellette, G., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Durocher, F., Simard, J., Knoppers, B.M., Joly, Y., Bridge, P. (2008). Genetic variants and haplotype analyses of the ZBRK1/ZNF350 gene in high-risk non BRCA1/2 French Canadian breast and ovarian cancer families. International Journal of Cancer. DOI
• Dorval, M., Bouchard, K., Maunsell, E., Plante, M., Chiquette, J., Camden, S., Dugas, M.J., Simard, J., Bessette, P., Bridge, P., Provencher, L., Francine Durocher, Knoppers, B.M., Laframboise, R., Lespérance, B., Pichette, R., Lépine, J., Voyer, P. (2008). Health behaviors and psychological distress in women initiating BRCA1/2 genetic testing: Comparison with control population. Journal of Genetic Counseling. DOI
• Aris, A., Lambert, F., Bessette, P., Moutquin, J.-M. (2008). Maternal circulating interferon-γ and interleukin-6 as biomarkers of Th1/Th2 immune status throughout pregnancy. Journal of Obstetrics and Gynaecology Research. DOI
• Plourde, M., Manhes, C., Leblanc, G., Durocher, F., Dumont, M., Sinilnikova, O., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Simard, J. (2008). Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. Journal of Molecular Endocrinology. DOI
• Plourde M, Samson C, Durocher F, Sinilnokova O, Simard J, INHERIT BRCAs. (2007). Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer. The Journal of steroid biochemistry and molecular biology. DOI
• Simard, J., Dumont, M., Moisan, A.-M., Gaborieau, V., Vézina, H., Durocher, F., Chiquette, J., Plante, M., Avard, D., Bessette, P., Brousseau, C., Dorval, M., Godard, B., Houde, L., Joly, Y., Lajoie, M.-A., Leblanc, G., Lépine, J., Lespérance, B., ... Goldgar, D. (2007). Erratum: Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer (Journal of Medical Genetics (2007) 44, (107-121)). Journal of Medical Genetics. DOI
• Simard, J., Dumont, M., Moisan, A.-M., Gaborieau, V., Vézina, H., Durocher, F., Chiquette, J., Plante, M., Avard, D., Bessette, P., Brousseau, C., Dorval, M., Godard, B., Houde, L., Joly, Y., Lajoie, M.-A., Leblanc, G., Lépine, J., Lespérance, B., ... Dugas, M. (2007). Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. Journal of Medical Genetics. DOI
• Durocher, F., Labrie, Y., Ouellette, G., Simard, J., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M. (2007). Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer. Journal of Human Genetics. DOI
• Guénard, F., Labrie, Y., Ouellette, G., Beauparlant, C.J., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Durocher, F., Bridge, P., Joly, Y., Knopper, B.M., Simard, J. (2007). Germline mutations in the breast cancer susceptibility gene PTEN are rare in high-risk non-BRCA1/2 French Canadian breast cancer families. Familial Cancer. DOI
• (2007). Microfluidic library screening for mapping antibody epitopes. ANALYTICAL CHEMISTRY. DOI
• Durocher, F., Labrie, Y., Soucy, P., Sinilnikova, O., Labuda, D., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Ouellette, G., Pichette, R., Plante, M., Tavtigian, S.V., Simard, J. (2006). Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families. BMC Cancer. DOI
• Moisan, A.-M., Fortin, J., Dumont, M., Samson, C., Bessette, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Provencher, L., Voyer, P., Goldgar, D., Bridge, P., Simard, J. (2006). No evidence of BRCA1/2 genomic rearrangements in high-risk French-Canadian breast/ovarian cancer families. Genetic Testing. DOI
• MacMillan HL, Patterson CJ, Wathen CN, Feightner JW, Bessette P, Elford RW, Feig DS, Langley J, Palda VA, Patterson C, Reeder BA, Walton R, Canadian Task Force on Preventive Health Care. (2005). Screening for depression in primary care: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. DOI
• Fortin, J., Moisan, A.-M., Dumont, M., Leblanc, G., Labrie, Y., Durocher, F., Bessette, P., Bridge, P., Chiquette, J., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Provencher, L., Voyer, P., Simard, J. (2005). A new alternative splice variant of BRCA1 containing an additional in-frame exon. Biochimica Et Biophysica Acta Gene Structure and Expression. DOI
• Antoniou, A.C., Durocher, F., Smith, P., Simard, J., Easton, D.F., Bessette, P., Bridge, P., Chiquette, J., Ptovencher, L., Laframboise, R., Lépine, J., Lespérance, B., Pichette, R., Plante, M., Voyer, P. (2005). BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Research. DOI
• (2005). Marker-specific sorting of rare cells using dielectrophoresis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. DOI
• Gerulath AH, Ehlen TG, Bessette P, Jolicoeur L, Savoie R, Society of Obstetricians and Gynaecologists of Canada, Gynaecologic Oncologists of Canada, Society of Canadian Colposcopists. (2002). Gestational trophoblastic disease. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.
• Trudeau, M., Stuart, G., Hirte, H., Drouin, P., Plante, M., Bessette, P., Dulude, H., Lebwohl, D., Fisher, B., Seymour, L. (2002). A phase II trial of JM-216 in cervical cancer: An NCIC CTG study. Gynecologic Oncology. DOI
• Garon G, LeHoux JG, Bessette P. (1999). Mutations in the gene encoding the alpha-subunit of the Gs protein in molar pregnancy. Endocrine. DOI
• (1999). A Phase II study of IncelTM (biricodar, VX-710) plus paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. CLINICAL CANCER RESEARCH.
• (1999). NCICCTG IND102: A phase II study of the oral platinum compound BMS-182751 in patients with advanced and or recurrent squamous cell carcinoma of the cervix. EUROPEAN JOURNAL OF CANCER. DOI
• (1999). Strategies for the expression of multidisulfide proteins in E-coli. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY.
• (1997). Reduction of the periplasmic disulfide bond isomerase, DsbC, occurs by passage of electrons from cytoplasmic thioredoxin. JOURNAL OF BACTERIOLOGY. DOI
• Petit, A., Geoffroy, P., Bessette, P., Bélisle, S. (1996). Expression of G proteins in human placentae from molar pregnancies. Placenta. DOI
• Petit A, Geoffroy P, Bessette P, Prévost J, Bélisle S. (1995). Expression of human placental G proteins during pregnancy. Journal of the Society for Gynecologic Investigation. DOI
• Petit, A., Geoffroy, P., Bessette, P., Prévost, J., Bélisle, S. (1995). Expression of Human Placental G Proteins During Pregnancy. Journal of the Society for Gynecologic Investigation. DOI

Articles de conférence

• Matulonis, U.A., Walder, L., Nøttrup, T.J., Bessette, P., Mahner, S., Gil-Martin, M., Kalbacher, E., Ledermann, J.A., Wenham, R.M., Woie, K., Lau, S., Marmé, F., Herraez, A.C., Hardy-Bessard, A.-C., Banerjee, S., Lindahl, G., Benigno, B., Buscema, J., Travers, K., ... Mirza, M.R. (2019). Niraparib maintenance treatment improves time without symptoms or toxicity (twist) versus routine surveillance in recurrent ovarian cancer: A twist analysis of the engot-ov16/ nova trial. Journal of Clinical Oncology. DOI

Autres contributions

Divers

• El-Zein, M., Ali, R., Farah, E., Botting-Provost, S., Franco, E.L., Lofters, A., Selk, A., Bodmer, B., Bouchard, C., McLachlin, M., Mansour, F.W., Ogilvie, G., Bentley, J., Blake, J., Smith, J.P., Murphy, J., Decker, K., Elit, L., Gilbert, L., ... Gotlieb, W.H. (2022). Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management. Medrxiv.